Benjamin F. Edwards & Company’s Astria Therapeutics ATXS Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ATXS Stock Details ATXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-333	Closed	-$4K	–	1757
2023 Q1	$4K	Hold	333	–	–	﹤0.01%	1574
2022 Q4	$5K	Hold	333	–	–	﹤0.01%	1552
2022 Q3	$3K	Hold	333	–	–	﹤0.01%	1630
2022 Q2	$1K	Hold	333	–	–	﹤0.01%	1732
2022 Q1	$2K	Hold	333	–	–	﹤0.01%	1643
2021 Q4	$2K	Hold	333	–	–	﹤0.01%	1621
2021 Q3	$3K	Hold	333	–	–	﹤0.01%	1585
2021 Q2	$4K	Hold	333	–	–	﹤0.01%	1536
2021 Q1	$6K	Hold	333	–	–	﹤0.01%	1455
2020 Q4	$4K	Hold	333	–	–	﹤0.01%	1432
2020 Q3	$12K	Hold	333	–	–	﹤0.01%	1221
2020 Q2	$13K	Hold	333	–	–	﹤0.01%	1215
2020 Q1	$8K	Hold	333	–	–	﹤0.01%	1316
2019 Q4	$12K	Hold	333	–	–	﹤0.01%	1367
2019 Q3	$11K	Hold	333	–	–	﹤0.01%	1359
2019 Q2	$16K	Hold	333	–	–	﹤0.01%	1261
2019 Q1	$16K	Hold	333	–	–	﹤0.01%	1192
2018 Q4	$9K	Buy	+333	New	+$12.6K	﹤0.01%	1304

Other funds holding ATXS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Benjamin F. Edwards & Company's ATXS Position: Q2 2023 in Review

Benjamin F. Edwards & Company sold out of Astria Therapeutics (ATXS) in Q2 2023, closing a stake of 333 shares — an estimated $4K sold.

Benjamin F. Edwards & Company first reported a position in ATXS in Q4 2018 and held it in 18 quarters. The position peaked at $16K in Q2 2019. 76 funds tracked by Wall St. Rank hold ATXS as of Q2 2023.

Benjamin F. Edwards & Company reported no remaining Astria Therapeutics position as of Q2 2023 after selling out during the quarter.
Benjamin F. Edwards & Company sold 333 Astria Therapeutics shares in Q2 2023, an estimated $4K.
Benjamin F. Edwards & Company first reported a position in Astria Therapeutics in Q4 2018 and held it in 18 quarters.
Benjamin F. Edwards & Company's Astria Therapeutics position peaked at $16K in Q2 2019.
76 funds tracked by Wall St. Rank held Astria Therapeutics as of Q2 2023.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2023, filed 15 Aug 2023.